HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME

Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions conta...

Full description

Saved in:
Bibliographic Details
Main Authors VALLÉE, Frédéric, CIBLAT, Stephane, SURPRENANT, Simon, BARABE, Francis, ABDOLI, Abbas, BELLA NDONG, Dominique, IZQUIERDO, Frédéric, PINTER, Thomas, BLACK, Cameron, PERRYMAN, Alexander, LIU, Bingcan, TRUONG, Vouy Linh, CRANE, Sheldon N, SZYCHOWSKI, Janek, DIETRICH, Evelyne, BOUCHARD, Alexanne
Format Patent
LanguageEnglish
French
Published 23.11.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use. Sont divulgués des composés et des sels pharmaceutiquement acceptables de ceux-ci qui peuvent être utilisés dans le traitement de sujets nécessitant un tel traitement. Les composés divulgués peuvent être des inhibiteurs de la tyrosine et de la kinase inhibitrice de cdc2 spécifique de la thréonine (Myt1). Sont divulgués également des compositions pharmaceutiques contenant les composés ou des sels pharmaceutiquement acceptables de ceux-ci ainsi que des procédés pour leur préparation et leur utilisation.
Bibliography:Application Number: WO2023CA50691